Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Neurophth and Hopstem Partner to Develop Stem Cell Therapies for Eye Diseases

publication date: Jun 2, 2021

Neurophth, a Wuhan company developing gene therapies for ophthalmic diseases, will partner with Hangzhou's Hopstem to develop a candidate using stem cells for ocular diseases including blindness. Hopstem has expertise in GMP manufacturing of clinical cell products derived from human induced pluripotent stem cells (hiPSC). It will receive upfront and milestone payments, plus royalties, to develop a candidate for a specific retinal degenerative disorder. Neurophth, which will have the option to license the candidate, will be responsible for its development and commercialization. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital